Amarillo Biosciences is developing low-dose oral interferon-alpha (IFNalpha; Veldona) as a potential treatment for primary Sjøgren's syndrome, oral mucositis in cancer patients, hepatitis B and C virus (HBV and HCV) infections, and bone marrow disorders. The company is also developing a topical formulation of IFNalpha for the potential treatment of genital warts. The product is registered in Ghana for the treatment of HBV infection. In October 2001, Amarillo licensed rights to its low-dose oral IFNalpha to Atrix Laboratories for the Orphan indications of oral papillomavirus and Behçet's disease.